Maintenance therapy in metastatic gastric cancer: a multicenter look from Colombia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter retrospective observational study conducted at four major cancer centers in Bogotá, Colombia. It analyzes adults who achieved at least stable disease after induction therapy and then received maintenance treatment with fluoropyrimidines, immunotherapy, or targeted agents between 2013 and 2023. The aim is to describe patient characteristics, treatment patterns, and outcomes to understand real-world use of maintenance strategies in Latin American settings. Data will be drawn from medical records and will focus on safety and survival endpoints, recognizing limitations inherent to retrospective analyses. The study builds on prior evidence suggesting maintenance therapy may reduce toxicity while maintaining disease control for metastatic gastric cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients older than 18 years diagnosed with metastatic gastric cancer at a participating institution between 2013 and 2023 who received fluoropyrimidines, immunotherapy or targeted therapy as maintenance therapy.
* At least stable disease according to RECIST criteria after initial induction treatment, with ECOG performance status of 2 or less, followed by maintenance therapy with fluoropyrimidines.
* Medical record showing institutional oncology follow-up.

Exclusion Criteria:

* Biopsies that do not meet the quality and adequacy criteria required for analysis.
* No clinical or imaging follow-up at the institution after diagnosis and treatment.
* Metastatic gastric cancer treated exclusively with palliative care without fluoropyrimidine maintenance chemotherapy.
* Discontinuation of fluoropyrimidine maintenance therapy before the first follow-up assessment because of toxicity or medical decision, without evaluation of treatment response.
* Death during the diagnostic process before tumor classification and staging were completed.

Where it's running

• Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
  Bogotá, Bogota D.C., Colombia Recruiting
• Clínica del Country
  Bogotá, Bogota D.C., Colombia Recruiting
• Hospital Universitario Fundación Santa Fe de Bogotá
  Bogotá, Bogota D.C., Colombia Recruiting
• Los Cobos Medical Center
  Bogotá, Bogota D.C., Colombia Recruiting

Study contacts

• Principal investigator: Henry Alexander Vargas, MD — Fundación Santa Fe de Bogotá
• Study coordinator: Henry Alexander Vargas, MD
• Email: henry.vargas@fsfb.org.co
• Phone: +57 601 6030303

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized ultrafractionated radiation plus immunotherapy for unresectable stomach cancer

  This study tests, in patients with unresectable locally advanced stomach cancer who have not progressed after initial therapy, whether adding PULSAR radiation to ongoing systemic treatment improves control of the tumor.

  Recruiting Samsung Medical Center · Seoul, Select Province/State · NCT07607119

• Conversion therapy with surgery and targeted para‑aortic radiotherapy for gastric cancer with retroperitoneal (station 16) lymph node spread

  This trial tests whether chemotherapy (SOX with or without a PD‑1 inhibitor), followed by D2 gastrectomy and para‑aortic radiotherapy, helps people with gastric adenocarcinoma who have only para‑aortic lymph node metastases live longer without their cancer progressing compared with standard chemotherapy alone.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07007182

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery

  A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.

  Recruiting at 8 sites The Affiliated Hospital of Qingdao University · Qingdao, Shandong and 7 other locations · NCT07898293

• Neoadjuvant immunotherapy plus Nab-P-SOX for locally advanced gastric/GEJ cancer

  This phase 2, single-arm study tests a pre-surgery treatment that combines a PD-1/CTLA-4 bispecific antibody with nab-paclitaxel, oxaliplatin, and S-1 in adults with HER2-negative, locally advanced gastric or GEJ cancer.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07867392

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.